ICIs for HCC: Cases

CME

Immunotherapy for Advanced HCC: Case Series

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: May 17, 2021

Expiration: May 16, 2022

Lipika Goyal
Lipika Goyal, MD, MPhil
Amit G. Singal
Amit G. Singal, MD, MS

Activity

Progress
1
Course Completed

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:

  • First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding risk
  • First-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding risk
  • First-line systemic treatment for a patient with Child-Pugh B liver function
  • Second-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumab
  • Management of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitor